Magnetic are to collaborate with the Stanford School of Medicine (Stanford, USA) around magnetic particle imaging for solving challenges in cell therapy and vascular imaging with magnetic particle imaging.
Christopher Contag, professor of paediatrics, radiology, bioengineering and of microbiology & immunology, will lead an effort to better understand early disease states in cancer and new therapeutic paths. Max Wintermark, professor of radiology and chief of neuroradiology at Stanford Health Care will also use the new imaging technology to perform quantitative cerebral perfusion and vascular studies in a variety of disease states, including stroke, traumatic brain injury, brain cancer, with the goal to eventually improve diagnosis and care in patients affected with these conditions.
The collaboration will focus on novel methods involving magnetic particle imaging to:
- Track cells in vivo to study early and minimal residue disease states of cancer
- Develop therapies targeting breast tumours
- Quantitative imaging of cerebral vessels and perfusion, and of permeability of the blood brain barrier in healthy and disease states
- Study inflammation response in stroke, traumatic brain injury and tumour
The Momentum Imaging system (Magnetic Insight) will be used in combination with Stanford’s capabilities in optical, nuclear, computed tomography and magnetic resonance imaging systems at the university’s Clark Center.
“We are excited to break new ground with magnetic particle imaging so that we can better understand early cancer biology with the goal of developing personalised therapeutic strategies. Magnetic particle imaging has the potential to offer unique insight into biological events unachievable with current technologies,” says Anna Christensen, president & chief executive officer of Magnetic Insight.
